<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>It is hard to discriminate <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>(<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) from many benign <z:e sem="disease" ids="C0018939" disease_type="Disease or Syndrome" abbrv="">hematological diseases</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>To identify the methylation status of zo-1 gene in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, the methylation specific PCR (MS-PCR) and reverse transcription-PCR (RT-PCR) were applied to detect the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> cell line MUTZ-1, bone marrow of a healthy donor and an <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> patient </plain></SENT>
<SENT sid="2" pm="."><plain>MS-PCR was also employed to detect the bone marrow of 72 patients with benign <z:e sem="disease" ids="C0018939" disease_type="Disease or Syndrome" abbrv="">hematological diseases</z:e>, 35 MDS-RA patients, and 20 MDS-like patients </plain></SENT>
<SENT sid="3" pm="."><plain>The results showed that <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> cell line MUTZ-1 displayed complete methylation of zo-1 promoter without <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression </plain></SENT>
<SENT sid="4" pm="."><plain>Inversely, a patient with benign <z:e sem="disease" ids="C0018939" disease_type="Disease or Syndrome" abbrv="">hematological disease</z:e> and a donor with <z:mpath ids='MPATH_458'>normal</z:mpath> bone marrow showed complete unmethylation of this gene with unaffected <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression </plain></SENT>
<SENT sid="5" pm="."><plain>No zo-1 promoter methylation was detected in patients with benign <z:e sem="disease" ids="C0018939" disease_type="Disease or Syndrome" abbrv="">hematological diseases</z:e>, while aberrant hypermethylation of zo-1 gene promoter were found in 48.6% (18/37) of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-RA patients </plain></SENT>
<SENT sid="6" pm="."><plain>The positive rate of zo-1 methylation in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-RA patients was higher than that in patients with benign <z:e sem="disease" ids="C0018939" disease_type="Disease or Syndrome" abbrv="">hematological diseases</z:e> (p &lt; 0.05) </plain></SENT>
<SENT sid="7" pm="."><plain>Seven suspected <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients manifested hypermethylation status of zo-1 gene (7/20), 2 were followed up for 1 year and transformed into <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>It is concluded that relatively high hypermethylation rate of zo-1 promoter is observed in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-RA, and no methylation in patients with benign <z:e sem="disease" ids="C0018939" disease_type="Disease or Syndrome" abbrv="">hematological diseases</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>Therefore, zo-1 gene hypermethylation may be served as a useful epigenetic marker in the differential diagnosis for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>